LLY
Eli Lilly and Company
- Depreciation and amortization, 2025
- $2.0B
- YoY, 2025
- +13.0%
- 5-year CAGR
- +8.6%
- 10-year CAGR
- +3.4%
Depreciation and amortization
Depreciation and amortization by fiscal year
| Period | D&A | YoY |
|---|---|---|
| 2025 | $2.0B | +13.0% |
| 2024 | $1.8B | +15.7% |
| 2023 | $1.5B | +0.3% |
| 2022 | $1.5B | −1.6% |
| 2021 | $1.5B | +16.9% |
| 2020 | $1.3B | +7.4% |
| 2019 | $1.2B | −23.4% |
| 2018 | $1.6B | +2.7% |
| 2017 | $1.6B | +4.7% |
| 2016 | $1.5B | +4.8% |
| 2015 | $1.4B | +3.5% |
| 2014 | $1.4B | −4.6% |
| 2013 | $1.4B | −1.1% |
| 2012 | $1.5B | +6.5% |
| 2011 | $1.4B | +3.4% |
| 2010 | $1.3B | +2.3% |
| 2009 | $1.3B | — |
| 2008 | −$1.1B | — |
| 2007 | −$1.0B | — |